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ABSTRACT
Purpose To investigate the mechanism behind the aggregation
breaking properties of dexamethasone phosphate and related
corticosteroids on the IgG1 antibody bevacizumab (Avastin®).
Methods An in silico 3D dimer model is developed to identify the
bevacizumab-bevacizumab interface, and different corticosteroids are
docked onto the model to distinguish preferred binding sites. In silico
predictions are validated by in vitro stability studies, where the antibody
is stressed in presence or absence of each corticosteroid and formed
aggregates are quantified by asymmetrical flow field-flow fractionation.
Results The dimer model features one close crystal contact area:
Lys445 on the Fc region interacts with one Fab arm of the second
bevacizumab. Docking reveals an interaction between the phos-
phate group of dexamethasone phosphate and Lys445, while the
rest of the molecule is hindering dimer formation. Predictions are
confirmed in vitro, demonstrating that dexamethasone phosphate
and betamethasone phosphate partly prevent antibody aggrega-
tion, whereas triamcinolone acetonide phosphate does not.
Conclusions Results suggest that bevacizumab monomers fol-
low a specific mechanism to form dimers in which a protein-
protein interaction hotspot can be distinguished. The dimer
formation can be hindered by corticosteroids in a specific way.
This approach allows a simple way to stabilize IgG1 antibodies.
KEY WORDS aggregation breaker . asymmetrical flow field-
flow fractionation . corticosteroids . molecular modelling .
monoclonal antibody
ABBREVIATIONS
AF4 asymmetrical flow field-flow fractionation
Ig immunoglobulin
MALS multi-angle light scattering
PDB protein data bank
SEC size exclusion chromatography
VEGF-A vascular endothelial growth factor A
INTRODUCTION
Therapeutic antibodies are currently the fastest growing
area of biopharmaceuticals with an average yearly mar-
ket growth rate of 35% since 2001 (1). The recent
developments of chimeric and fully-humanized monoclo-
nal antibodies have spawned an unprecedented interest
in using these molecules as therapeutic agents, since
they can specifically target molecules implicated in
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disease, thereby essentially side-stepping the secondary
effects that may be associated with conventional drug
therapies.
The development of stable antibody formulations is chal-
lenging, since they have the tendency to be physically and
chemically instable in aqueous media. Antibodies are, for
example, susceptible to denaturation, aggregation and co-
valent modifications (2,3). Degradation of antibody formu-
lations due to aggregation phenomena is a particular
problem. The formation of aggregates might lead to a
reduced efficacy of the protein drug. Since aggregates can
increase the immunogenicity of the antibody (4), clinical side-
effects might occur. Antibody aggregation is also a source of
batch-to-batch variations in the antibody production chain
and its control leads to regulatory and quality control burdens
with their associated costs. Furthermore, the propensity of
antibodies to aggregate decreases the stability of the formula-
tion, which negatively affects product shelf-life (5).
Like for most other proteins, antibody stability
depends on many factors, like protein concentration,
pH, ionic strength, temperature and agitation. Predict-
ing whether an antibody will aggregate is challenging,
notably because each antibody may have a very specific
and characteristic stability profile (6). Moreover, due to
the complexity of the antibody structure, identification
of the precise nature of the antibody-antibody interac-
tion and contact surfaces of aggregates remains chal-
lenging (7). A number of approaches have been
investigated to improve antibody stability, including the
addition of “stabilizing” agents to the protein formula-
tion. Examples of these agents are polysorbate-based
surfactants (8), amino acids (9), glucose (10), sorbitol
(10), and dextran sulphate (9). Unfortunately, their suc-
cess has been limited, mainly due to the fact that most
of these agents are directed at optimizing the environ-
ment surrounding the antibody, and not specifically at
interfering with the interaction hotspot involved in the
formation of aggregates. Another concept to ameliorate
the stability of the protein drug is to mutate single
amino acids in Igs to specifically target hydrophobic
patches implicated in aggregation (7). However, such
an approach necessarily modifies the structure of the
Ig, possibly affecting both the clinical efficacy and im-
munogenicity of the protein drug.
The humanized monoclonal IgG1 antibody bevacizu-
mab (Avastin®) is registered for the treatment of different
forms of cancer and has also been widely used off-label for
the ophthalmic indication age-related macular degenera-
tion. It acts by blocking vascular endothelial growth factor
A (VEGF-A), thereby inhibiting neovascularisation and
leakage of blood vessels (11). The present study is based on
a clinical observation made earlier by our group (12), in
which the combination of bevacizumab with the anti-
inflammatory drug dexamethasone disodium phosphate
led to a decrease in aggregate formation. The rationale
behind the combination of bevacizumab with dexameth-
asone phosphate is the fact that the latter also sup-
presses the formation of new leaky blood vessels.
Thus, a synergistic effect might be obtained through
combination therapy (13).
The aims of this study are to clarify the mechanisms
behind this protective process through a combination of
in silico and in vitro studies. The formation of bevacizu-
mab dimers is investigated by homology modelling and
the interactions between several anti-inflammatory drugs
and the antibody are studied by molecular docking.
Outcomes of the in silico work are experimentally vali-
dated through in vitro stability studies on the combined
formulations using Asymmetrical Flow Field-Flow Frac-
tionation and Size Exclusion Chromatography coupled
to Multi-Angle Light Scattering (AF4-MALS and SEC-
MALS).
MATERIALS AND METHODS
Molecular Modelling
Template Identification and Alignment
Bevacizumab is a humanized antibody formed by a Fab
region responsible for recognizing antigens and a Fc region
derived from IgG1. The Protein Data Bank (PDB) (http://
www.rcsb.org) (14,15) was surveyed for suitable crystal
structures to be used as structural templates for homology
modelling. Three structures were found: the bevacizumab
Fab moieties in complex with the human VEGF (PDB id:
1BJ1) (16) and two full length IgG1 antibodies, a human
(PDB id: 1HZH) and a murine one (PDB id: 1IGY). Because
bevacizumab is a humanized antibody, the human antibody
logically should be taken as template. However, the only
full-length human IgG1 crystallized so far (PDB id: 1HZH)
has an unusual crystal symmetry (H32) and strongly dis-
torted orientations of the Fabs with respect to the axis of
the Fc region (17). In contrast, the intact murine IgG1κ
is a template with a more usual overall 3D structure.
With a resolution of 3.2 Å (PDB id: 1IGY), this structure
is acceptable as template. To humanize its hinge and Fc
regions, the residues were mutated so as to match the
sequence of the structure 1HZH. All sequence alignments
were carried out with ClustalW (18,19) in the Biology
Workbench 3.2 (San Diego Supercomputer Center;
http://seqtool.sdsc.edu/CGI/BW.cgi). To nonetheless
compare the symmetric murine configuration with an
asymmetric model, the human template (1HZH) was
used to build a second model.
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3D Model Building and Validation
The initial 3D model of bevacizumab was carried out using
Sybyl 8.0 (Tripos Inc., St. Louis, MO, USA). The Fabs of
IgG1 (1IGY) were structurally superposed and thereafter
replaced with the ones of bevacizumab (1BJ1). Then, the
bevacizumab Fabs were connected with the hinge-Fc of
IgG1 (1IGY) and finally, the hinge-Fc region was human-
ized using the sequence of 1HZH. The connecting region of
the model was submitted to energy minimization using
Sybyl 8.0 default parameters while keeping the disulfide
bridges intact. The quality of the resulting model was
assessed using Procheck (20). A Ramachandran plot analysis
(in Procheck) of the amino acid conformations was carried
out using a resolution mean between the crystal structures of
both the Fc (resolution of 1IGY: 3.2 Å) and the Fabs
(resolution of 1BJ1: 2.4 Å). Critical side chains were
corrected for distortion in Sybyl 8.0 and the refinement
procedure (manual adjustments and minimization) was re-
peated until reaching φ and ψ angles in the Ramachandran
plot that were comparable to the input crystal structures.
An analogous procedure was applied for the second model
based on 1HZH.
3D (Dimer) Aggregation Model
A 3D aggregation model was built to identify the
bevacizumab-bevacizumab interface, with the idea in
mind that crystal contacts represent privileged protein-
protein interfaces. Based on the crystal symmetries of
the IgG1 structure 1IGY and subsequently on the IgG1
structure 1HZH, putative crystal contacts between two
full length bevacizumabs were defined using SwissPDB-
Viewer 4.0.1 (21). For the 3D aggregation model based
on 1IGY, the crystallographic symmetry (P21) of the
IgG1 crystal structure was applied to obtain a layer,
which was translated along the unit cell, and to recreate crystal
contacts. The first translation, featuring the only close crystal
contact between the monomers in the order of 4 Å, was saved
in pdb format and the bevacizumab model overlaid according
to the carbon α atom positions in Sybyl 8.0. The second model
based on the crystal structure of 1HZH was obtained by
applying the same procedure. Its translation according to the
crystal symmetry of 1HZHwas also displayed to verify whether
close crystal contacts would occur in the same region for this
asymmetric conformer as for the symmetric 1IGY.
Docking Dexamethasone Phosphate and Similar Anti-Inflammatory
Drugs onto the Bevacizumab Monomer
Dexamethasone phosphate and two similar, commercially
available anti-inflammatory drugs (betamethasone phos-
phate and triamcinolone acetonide phosphate) were docked
onto the bevacizumab monomer to see where they were
binding preferentially, whether binding took place in the
aggregation zone and if so, how the observed binding pro-
pensities could be related to properties of the small mole-
cules and the binding site, respectively. The small molecule
setup for docking was done in Sybyl 8.0. Hydrogens were
added to the small molecular weight molecule, the phos-
phate group was left unprotonated and Gasteiger-Hückel
charges were calculated and added. Each resulting molecule
was minimized using 100 steps of the default Powell mini-
mization protocol of Sybyl 8.0. Systematic flexible docking
with standard parameters was then performed with FlexX
3.1.3 (Biosolveit GmbH) all over the bevacizumab antibody
surface (monomer: Fabs, hinge and Fc), previously divided
into several segments of 10 Å around each arginine and
lysine. By adopting this strategy, roughly 90% of the whole
antibody surface and all major cavities were included in the
docking study.
Based on the binding propensities of dexamethasone
phosphate at the bevacizumab-bevacizumab interface and
the physicochemical properties of the ligand and the binding
site on one monomer, a putative mechanism of action was
postulated. This mechanism was subsequently verified by
docking betamethasone phosphate and triamcinolone ace-
tonide phosphate in the same way as described for dexa-
methasone phosphate, in order to find out whether they
would bind in the antibody-antibody contact region. Ten
docking poses per molecule and docking site were kept, as
this number revealed later to be sufficient to distinguish
between aggregation breakers and non-aggregation breakers.
The poses were scored with the FlexX scoring function.
Evaluation of docking results was based on the attrib-
uted bevacizumab-small molecule interactions score, and
the subsequent visual inspection was performed by con-
sidering the context of both the monomer and the
dimer antibody models, using a cylindric “volume of
interference” (Supplementary Material, Figure S1). The
best-ranked poses projecting roughly orthogonally out-
wards from the bevacizumab surface and thus enclosed
by this volume of interference, were retained.
In Vitro Experiments
Sample Preparation
Three anti-inflammatory drugs were tested for their aggre-
gation breaking properties, following the modelling
outcomes:
i. Dexamethasone 21-phosphate disodium salt (Sigma-
Aldrich, Lausanne, Switzerland),
ii. Betamethasone 21-phosphate disodium salt (Sigma-
Aldrich, Lausanne, Switzerland), and
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iii. Triamcinolone acetonide-21-phosphate dipotassium
salt solution (Kenacort A Solubile, Dermapharm AG
Arzneimittel, Grünwald, Germany).
All were combined with bevacizumab (Avastin®, Roche
Pharma, Reinach, Switzerland) in a 1:150, 1:15 and/or
1:1.5 molar ratio (antibody : anti-inflammatory drug). Ra-
tios were derived from clinical studies in which bevacizumab
was combined with dexamethasone disodium phosphate in
a molar ratio of 1 mol bevacizumab versus 150 mol dexa-
methasone disodium phosphate (13).
Bevacizumab was used as commercial formulation,
hereinafter referred to as Avastin®, in which the anti-
body is formulated in a 51 mM phosphate buffer pH
6.2 with 60 mg/ml α,α-trehalose dihydrate and 0.04%
polysorbate 20, or was dialyzed overnight (Pierce Slide-
A-Lyzer Dialysis Cassette, Reactolab, Servion, Switzer-
land) into 50 mM phosphate buffer at pH 7, hereinafter
referred to as bevacizumab. The concentration of bev-
acizumab was kept at 25 mg/ml in all series to simulate
the concentration of the commercial formulation, since
dilution may lead to reversion of small aggregates into
monomers (6). After dialysis, the antibody formulation
was combined directly with one of the three anti-
inflammatory drugs or incubated at 40°C for one week,
before addition of the anti-inflammatory drugs. Tem-
perature and pH were chosen in order to accelerate the
formation of aggregates, since an ongoing aggregation
process is needed to observe a stabilizing effect of the
different anti-inflammatory drugs in a reasonable time
frame. Osmolality and pH were controlled and stayed
constant over the duration of the study. The pH and
osmolality of the samples containing antibody alone
were similar to those in which the antibody was com-
bined with a corticosteroid. Over time, all samples
remained clear solutions and no insoluble aggregates
were observed upon visible inspection.
It should be noted that the commercially available product
Avastin® contains 0.04% polysorbate 20. Although the prod-
uct was dialysed for a part of the studies, this does not lead to
the complete removal of polysorbate (22). Thus, it should be
taken into account that all observed effects of the corticosteroids
on the antibody occur in the presence of this surfactant.
Inter-sample variability was observed when different
batches of Avastin® were dialysed, with a maximum vari-
ability of 11%. In other words, the same treatment and
stress did not always lead to the same amount of aggregates,
possibly due to an inter-batch variability in the polysorbate
concentration (22). Therefore, comparisons were always
made on the same batch, meaning that the sample to which
the corticosteroid was added was always compared with a
sample of the antibody alone from the same batch.
Series I: Effect of Dexamethasone Phosphate on Aggregation
Formation Induced by Temperature Stress
Three different concentrations of dexamethasone phosphate
in 51 mM phosphate buffer pH 6.2 were added to the com-
mercial formulation of Avastin® to obtain Avastin:dexameth-
asone disodium phosphate molar ratios of 1:1.5, 1:15 and
1:150. To the sample containing the antibody alone, the same
volume of 51 mM phosphate buffer pH 6.2 was added, to
avoid differences in antibody concentration between the sam-
ples with and without anti-inflammatory drug. After addition,
Avastin® alone and the combined formulations were all
stored for 35 days at 40°C. Samples were analysed directly
after preparation (t0) and after 7, 14 and 35 days. Based upon
the outcomes of this series, in which the 1:15 molar ratio
showed to be optimal, it was decided to perform all other
series with this particular molar ratio.
Series II: Effect of Dexamethasone Phosphate on Aggregation
Formation Induced by Mechanical Stress
Bevacizumab was combined with dexamethasone phos-
phate in a 1:15 molar ratio, after dialysis of the antibody
into 50 mM phosphate buffer at pH 7. The same volume of
buffer was added to the sample containing antibody alone.
Both samples were placed vertically in a Thermomixer
(Thermomixer Comfort, Eppendorf AG, Hamburg,
Germany) and were horizontally shaken at controlled
room temperature for 48 h at 1,000 rpm. Samples were
analysed at t0 and at 1, 4, 24 and 48 h.
Series III: Effect of Three Anti-Inflammatory Drugs on Prestressed
Antibody
Bevacizumab was dialysed into 50 mMphosphate buffer at pH
7 and stored at 40°C for 7 days. After 7 days, dexamethasone
phosphate, betamethasone phosphate and triamcinolone ace-
tonide phosphate were added to the antibody in a 1:15 molar
ratio. The same volume of buffer was added to the sample
containing antibody alone. All samples were stored for 28 days
at 40°C and analysed at t0 and after 1, 7, 14 and 28 days.
Series IV: Effect of Dexamethasone Phosphate on Prestressed
Fab Fragment
The stabilizing properties of dexamethasone phosphate on
the commercially available Fab-fragment ranibizumab
(Lucentis®, Novartis Pharma Schweiz AG, Bern, Switzer-
land) were investigated as well. Ranibizumab was dialysed
overnight into a 50 mM phosphate buffer at pH 7 and
concentrated to 10 mg/ml (based on the concentration of
the commercial formulation). Since the fragment is very
stable, the sample was stored for 1 year at 25°C before the
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addition of dexamethasone disodium phosphate in a
1:15 molar ratio. To the sample that contained the Fab
fragment alone, a similar volume of buffer was added. Both
the sample of ranibizumab alone and the combined formu-
lation were stored for 28 days at 40°C. Samples were
analysed at t0 and after 1, 7, 14 and 28 days.
Sample Analysis
Asymmetrical Flow Field-Flow Fractionation. All samples were
analyzed by asymmetrical flow field-flow fractionation (AF4)
(Wyatt Technology Europe GmbH, Dernbach, Germany),
coupled to multi-angle light scattering (MALS) and UV spec-
troscopy at 280 nm (23). This technique allows the measure-
ment of aggregates up to the subvisible range (24). Samples
were injected undiluted; the injection volume per run
depended on the concentration of the formulation and was
0.5 μl for bevacizumab (25 mg/ml) and 1.0 μl for ranibizu-
mab (10 mg/ml). The applied mobile phase was similar to the
buffer of the analyzed formulations, i.e. 51 mM phosphate
buffer pH 6.2 for the commercial formulation and 50 mM
phosphate buffer pH 7.0 for the dialysed samples. MALS
detection allowed calculating the weight-average molar mass
of the antibody fractions that were separated by AF4, thus
providing information on the aggregation state of the partic-
ular fraction (a fraction with a molar mass of e.g. twice the
monomer contains dimers, etc.). Bevacizumab and ranibizu-
mab concentrations were determined by UV spectroscopy,
based upon an extinction coefficient of 1.7 and 1.8 cm*ml/
mg, respectively. Data collection and analysis were done using
Astra software (version 5.1.9.1, Wyatt Technology Europe
GmbH, Dernbach, Germany) and the different fractions were
classified as monomers, dimers, trimers or higher order aggre-
gates. Because of the low inter-sample variability observed
over time using this method (12), one sample container was
stored for all samples and analyses were carried out in tripli-
cates. All data were reported as average percentage of mono-
mers/aggregates±standard deviation (SD) (n03). Pair-wise
comparisons were carried out to compare the antibody alone
with the combined formulations using a Mann–Whitney U
test (exact one-tailed significance, p≤0.05).
Size Exclusion Chromatography. In order to confirm the data
obtained by AF4 using an orthogonal technique, part of the
samples was analysed by size exclusion chromatography
(SEC) as well. A TSK G3000 SWXL column, 7.8×300 mm
(Tosoh Bioscience GmbH, Stuttgart, Germany) was com-
bined with the same UV and MALS detectors used for the
AF4 analyses. Separation was performed at 25°C at a flow
rate of 0.5 ml/min, using a 200 mM potassium phosphate
buffer with 250 mM KCl pH 7.0 as a mobile phase. 2 μl
undiluted sample were injected per run. Data collection and
analysis were performed as described for AF4.
RESULTS
Molecular Modelling
3D Monomer- and Aggregation Model
The geometric quality of the final “symmetric” monomer
model based on 1IGY (Fig. 1) consisting of the bevacizumab
Fabs and the humanized hinge-Fc is comparable to that of the
input template structures, with 74.9% of the residues in the
model found inmost favoured, 21.4% in additionally allowed,
2.2% in generously allowed and 1.5% in disallowed areas of
the Ramachandran plot. The aggregation model obtained by
replicating the monomer model according to the crystal sym-
metry (P21) of themurine IgG1 (PDB id: 1IGY) (Fig. 1a) shows
a single specific close contact area (least distance in the order
of 4 Å) between the two monomers (Fig. 1b). The bottom of
one Fc comes to lie in between the two Fab regions of the
other bevacizumab monomer. More specifically, this specific
contact is characterized by the interaction of Ser202 (1BJ1
naming and numbering), belonging to one Fab arm of one
bevacizumab, and Lys445 (1HZH and 1IGY naming and
numbering), which is part of the Fc region of the second
bevacizumab. Lys445 and Ser202 form the major interaction
between the monomers and are fully conserved in engineered
IgG1-based sequences (Supplementary Material, Figures S2-
S6). The amino acids lining the contact area include for the
Fab region His198 to Pro204 (1BJ1 naming and numbering)
and for the Fc region Met381 to Val386 and Val443 to
Glu449 (1IGY naming and numbering). Comparing the mu-
rine (PDB id: 1IGY) with the human Fc (PDB id: 1HZH), the
residues surrounding and including Lys445 are well conserved
from a sequence (Supplementary Material, Figure S2A) and
structural (Supplementary Material, Figure S5) point of view.
The non-conserved amino acids are not involved in inter-
antibody interactions and are thus thought to only marginally
affect the prediction outcomes for potential aggregation
breakers. The aggregation model based on the human frame-
work shows, similar to the murine model, a close contact area
between the region around Lys445 and the Fab fragment,
although due to the asymmetric Fab arrangement, another
region on the Fab is involved. As expected for a Fab region,
this region is not fully conserved among pharmaceutically
relevant antibodies (Supplementary Material, Figure S7),
but the hydrophilicity of the corresponding residues is
conserved.
Docking of Anti-Inflammatory Drugs
Concerning the docking of the steroids all over the mono-
mer antibody model, highest docking scores (reflecting the
antibody-small molecule interaction energy) are obtained
for phosphate-containing steroids binding to Lys445 at the
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aggregation interface. Interactions with other lysines are less
favourable, and the docking poses around different argi-
nines receive even lower scores. For all shown docked com-
pounds, a strong electrostatic interaction between the
phosphate of the ligand and the Lys445 side chain is noted
(Fig. 2d for dexamethasone phosphate, Fig. 2e for betame-
thasone phosphate and Fig. 2f for triamcinolone acetonide
phosphate). To provide an order of the strength of this
interaction, an exposed salt bridge is known to be as strong
as a neutral H-bond (5±1 kJ/mol) (25,26). Additional H-
bonds between residues adjacent to Lys445 and the phos-
phate further stabilize the steroid in the binding pocket.
Among the steroids docked to this region, the propensity
of the 10 generated poses to interfere with the adjacent
antibody was highest for dexamethasone phosphate and
betamethasone phosphate, with the higher scored docking
poses all interfering. For triamcinolone acetonide phos-
phate, this propensity was only at 3 out of 10 poses. Because
in our case, the docking scores were not informative with
respect to their antibody-antibody breaking ability, we first
displayed the docking poses of each small molecule on the
aggregation model and then visually defined a « volume of
interference » (Supplementary Material, Figure S1). The
simplest geometric shape including all the dexamethasone
phosphate or betamethasone phosphate aggregation break-
ing poses was defined using a cylinder. The centre of its base
was put to the Cα atom of Lys445, with the plane of the base
including the N atom of Lys445, and the radius was set to
7 Å. A height of 12 to 15 Å was drawn orthogonally from
the base using Fc atoms situated approximately on the
surface of the circle in vicinity of the adjacent Fab of the
other antibody monomer. All docked steroids overlap in
vicinity to the Fc, with their phosphates binding to the
Lys445 side chain. While dexamethasone phosphate and
betamethasone phosphate are interfering with the Fab of
the adjacent antibody, triamcinolone acetonide phosphate is
generally not. A score of 5 was obtained for dexamethasone
phosphate and betamethasone phosphate, while a score of 2
was obtained for triamcinolone acetonide phosphate. The
same scores were also achieved when generating 100 docking
poses. Figures 2a, b and c are representative figures showing
how dexamethasone phosphate, betamethasone phosphate
and triamcinolone acetonide phosphate are positioned on the
monomer. The moieties of dexamethasone phosphate and
betamethasone phosphate that are clashing with the second
monomer in the aggregationmodel are clearly visible in Fig. 2g
and h, respectively. In contrast, triamcinolone acetonide phos-
phate does not clash into the second monomer (Fig. 2i), which
is probably due to the acetonide part that confers rigidity and a
different spatial orientation to the compound.
In Vitro Experiments
Series I: Effect of Dexamethasone Phosphate on Aggregation
Formation Induced by Temperature Stress
Over time, storage at 40°C leads to differences in the
decrease in monomer percentage for Avastin® alone or in
presence of dexamethasone phosphate (Supplementary
Material, Figure S8). The association of Avastin® with dexa-
methasone phosphate after 35 days of storage at 40°C is
depicted in Fig. 3 (and Supplementary Material, Table SI).
The commercial product alone comprises 88.3±0.2% of
monomers, e.g. 11.7±0.2% of the antibody has formed
1 close 
contact 
area
Ser202Lys445
a
b
Fig. 1 The 3D aggregation model (a) of bevacizumab and a zoom on the contact region (b). The aggregation model was obtained by replicating the
monomer model according to the crystal symmetry (P21) of the template IgG1. The least distance in the contact region between Lys445 (mouse and
human IgG1 naming and numbering, PDB ids: 1IGYand 1HZH) and Ser202 (bevacizumab Fab naming and numbering, PDB id: 1BJ1) is in the order of 4 Å.
The colouring gradient of the electrostatic potential surface goes from blue for negatively charged to red for positively charged atoms. (a) and (b) were
prepared using Sybyl 8.0 (Tripos Inc.) and MOE 2011 (Chemical Computing Group), respectively.
Dexamethasone as IgG1 Aggregation Breaker 1181
aggregates, consisting of dimers (10.16±0.04%) and trimers
(1.5±0.2%). The stabilizing effect of dexamethasone phos-
phate is observed for all three molar ratios, being most pro-
nounced for the 1:15 combination, which contains only 4.3±
0.5% dimers and 0.2±0.2% trimers. All three combined
formulations show a significant difference in aggregation per-
centages compared to Avastin® alone (Mann–Whitney U,
one-tailed p≤0.05). Very low percentages of higher order
aggregates (0.1±0.2% decamers) were only observed for the
1:150 molar ratio.
Series II: Effect of Dexamethasone Phosphate on Aggregation
Formation Induced by Mechanical Stress
Figure 4 shows the stabilizing effect of dexamethasone phos-
phate on bevacizumab during stress through agitation. Me-
chanical stress of the sample of bevacizumab alone leads to
increased aggregation: The total percentage of aggregates
doubles from 9.2±0.6% after one hour of agitation to 18±
1% after 48 h. In contrast, after one hour of agitation, the
combined formulation (with a 1:15 molar ratio) shows an
aggregation breaking effect, attributed to the presence of
dexamethasone phosphate: Instead of 9.2±0.6%, a total
aggregate percentage of 4.2±0.2% is measured. This per-
centage even slightly decreases to 3.8±0.2% after 48 h of
agitation, indicating a stabilizing effect as well. The aggre-
gation species that are observed are dimers and trimers for
both samples. Differences in the amount of aggregates be-
tween the samples are significant (Mann–Whitney U, one-
tailed p≤0.05) at all time points.
Series III: Effect of Three Anti-Inflammatory Drugs on Prestressed
Antibody
The addition of betamethasone phosphate in a 1:15 molar
ratio to the prestressed antibody shows aggregation breaking
properties of the corticosteroid (Fig. 5). The results are
comparable to the formulation in which dexamethasone
phosphate is combined with the prestressed antibody
(Table I, Fig. 5). After 28 days, 63.3±0.5% of monomers
a d
Ser446
Gln449
Lys445
g
b e
Asn392
Ser446
Gln449
Lys445
h
c f
Asn392
Lys445
Asp444
Ser446
i
Fig. 2 Representative docking poses of dexamethasone phosphate (a, d and g), betamethasone phosphate (b, e and h) and triamcinolone acetonide phosphate
(c, f and i), respectively. Docking poses on the bevacizumab monomer are displayed in a, b and c using MOE 2011 (Chemical Computing Group). Interactions
between the docked steroid and the bevacizumab monomer are drawn in a schematic way in d, e and f using SymyxDraw 3.3. The dotted lines represent H-
bonds or electrostatic interactions and the cyan box the parts of the steroid that clash with the second monomer of the aggregation model. The same poses are
also represented in the aggregation model (g, h, i). MOE (Chemical Computing Group) was used for producing the monomer and dimer views, where the
carbon atoms of the steroids are drawn in grey. The colour gradient for the electrostatic potential surface is the same as for Fig. 1.
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Fig. 3 Avastin® commercial
formulation alone (Ava) and in
combination with dexametha-
sone phosphate (dex) in a 1:1.5,
1:15 and 1:150 molar ratio after
35 days of storage at 40°C.
Quantification of aggregates was
performed by AF4 coupled to
MALS. Percentages of aggregates
are expressed as average ± SD
(n03), dark grey 0 dimers, light
grey 0 trimers, intermediate grey 0
higher order aggregates. * Sig-
nificantly different from the
percentage of aggregates of
Avastin® alone (Mann–Whitney
U test, p≤0.05, exact one-tailed
significance).
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Fig. 4 Bevacizumab alone
(beva) and in combination with
dexamethasone phosphate in a
1:15 molar ratio (dex). Samples
were stressed by agitation during
48 h. Quantification of aggregates
was performed by AF4 coupled
to MALS. Percentages of aggre-
gates are expressed as average ±
SD (n03), dark grey 0 dimers,
light grey 0 trimers. *Significantly
different from the percentage of
aggregates of bevacizumab alone
(Mann–Whitney U test, p≤0.05,
exact one-tailed significance).
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are present in the bevacizumab sample, compared to 80.73±
0.06% for the combination with dexamethasone phosphate
(Table I) and 79.9±0.3% for betamethasone phosphate
(results not shown). Differences in aggregation between the
antibody alone and the combined formulations are significant
(Mann–Whitney U, one-tailed p≤0.05). Moreover, the aggre-
gated fractions of both combined formulations only consist of
dimers (19.27±0.06% and 20.1±0.3%, respectively), while
the antibody alone forms both dimers (26.5±0.1%) and
trimers (10.3±0.4%) (As depicted for bevacizumab
alone or in combination with dexamethasone phosphate
in Supplementary Material, Figure S9).
In order to check the data obtained by AF4 with an
orthogonal technique, the combination of the prestressed
antibody with dexamethasone phosphate was investigated
by SEC. The percentages of monomers found by SEC are
in agreement with those detected by AF4, especially consid-
ering the fact that both analyses were carried out on differ-
ent vials (Table I). Thus, these data confirm the aggregation
breaking properties of dexamethasone phosphate on the
IgG1-based antibody. It should be noted that SEC detects
more separate fractions than AF4: Fragments and higher
order aggregates are present in the samples analysed by
SEC, but absent when the analyses are performed by AF4.
It is unclear whether these fractions are created during the
analysis, or whether SEC enables better separation.
In contrast to the aggregation breaking effect seen with
dexamethasone phosphate and betamethasone phosphate,
the addition of triamcinolone acetonide phosphate only has
an effect at t1, thereafter the combination does not significantly
affect the aggregation profile of the antibody (Supplementary
Material, Figures S10 and S11). The samples with and without
steroid drug show similar percentages of aggregates after
28 days of storage: In the bevacizumab sample, 20.8±0.6%
of dimers, 3.5±0.2% of trimers and 0.9±0.2% of higher order
aggregates are present, compared to 20.2±0.2% of dimers,
3.5±0.2% of trimers and 0.95±0.09% of higher order aggre-
gates for the combined formulation.
Series IV: Effect of Dexamethasone Phosphate on Prestressed
Fab Fragment
The percentages of formed aggregates after 28 days are
represented in Table II, both for the prestressed
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Fig. 5 Percentage of monomers for bevacizumab alone (black curve) and
in combination with dexamethasone phosphate (black dashed curve) and
betamethasone phosphate (grey curve) in a 1:15 molar ratio after 28 days at
40°C. Quantification of aggregates was performed by AF4 coupled to
MALS. Bevacizumab was stressed for 7 days at 40°C before the addition
of the steroid drugs. Percentages are expressed as average±SD, shown as
vertical bars (n03).
Table I Prestressed Bevacizumab (7 Days at 40°C) Alone and in Com-
bination with Dexamethasone Phosphate in a 1:15 Molar Ratio After
28 Days at 40°C
AF4 Bevacizumab Bevacizumab + dexamethasone
phosphate 1:15
Fragments (%) Not detected Not detected
Monomers (%) 63.3±0.5 80.83±0.06*
Dimers (%) 26.5±0.1 19.27±0.06
Trimers (%) 10.3±0.4 Not detected
Higher order aggregates (%) Not detected Not detected
SEC Bevacizumab Bevacizumab + dexamethasone
phosphate 1:15
Fragment (%) 1.7±0.1 2.3±0.1
Monomers (%) 60.7±1.1 82.9±0.3*
Dimers (%) 26.5±0.5 12.3±0.3
Trimers (%) 8.5±0.4 1.93±0.04
Higher order
aggregates (%)
2.6±0.2 0.62±0.02
Quantification of monomers/aggregates was performed by AF4 coupled to
MALS and by SEC coupled to MALS. Percentages are expressed as
average ± SD (n03).
*Significantly different from the percentage of monomers of bevacizumab
alone (Mann–Whitney U test, p≤0.05, exact one-tailed significance).
Table II Prestressed Ranibizumab (365 Days at 25°C) Alone and in
Combination with Dexamethasone Phosphate in a 1:15 Molar Ratio
AF4 Ranibizumab Ranibizumab + dexamethasone
phosphate 1:15
Monomers (%) 51.8±0.5 50.0±0.4
Dimers (%) 15.4±0.4 14.9±0.9
Trimers (%) 8±1 7±1
Higher order
aggregates (%)
25±1 27.6±0.4
Quantification of monomers/aggregates was performed by AF4 coupled to
MALS. Percentages are expressed as average ± SD (n03). No significant
difference was observed between the samples with and without dexa-
methasone phosphate (Mann–Whitney U test, p≤0.05, exact one-tailed
significance).
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ranibizumab alone and for the combination with dexameth-
asone phosphate in a 1:15 molar ratio. The addition of
dexamethasone phosphate has no stabilizing effect on the
Fab fragment; the monomer percentages that are present in
both samples are comparable (51.8±0.5% for ranibizumab
alone vs. 50.0±0.4% for the combined formulation). All
measured aggregation species (dimers, trimers and higher
order aggregates) are also comparable between both groups
of samples.
DISCUSSION
In this study, the aggregation breaking properties of dexa-
methasone phosphate on the monoclonal antibody bevaci-
zumab are investigated. Construction of a 3D aggregation
model and small molecule docking allow comprehending
the process through which aggregation might occur and
how an aggregation breaker might interfere with this mech-
anism. Furthermore, the requirements that have to be met
by a small molecule to be a breaker can be predicted
(structure-activity relationship). The combination with in
vitro stability studies provides a validation of the observations
made in silico.
It should be noted that the 3D model focuses on the onset
of aggregation; only the formation of dimers was investigat-
ed. Moreover, the native structure of the antibody was used,
while it is generally assumed that especially partly unfolded
antibodies are prone to aggregation (27,28). Computational
prediction of unfolding would however require time- and
resource-intensive molecular dynamics, which would go be-
yond the scope of this work. Besides, reversible self-
association of native state proteins is possible through hy-
drophobic or electrostatic interactions; with or without sub-
tle conformational changes (6,29). The term “aggregation”
that is used throughout the paper therefore refers to “self
association of native state monomers” in this particular
context.
Based on the symmetry and space group found in the
crystal structures of 1IGY and 1HZH, respectively, a «
symmetric » (replicated according to the crystal symmetry
of 1IGY) and an « asymmetric » (replicated according to the
crystal symmetry of 1HZH) bevacizumab model were built.
Both aggregation models reveal a contact zone situated on
the Fc tip region around Lys445 of the first bevacizumab
and a variable interacting region on one Fab of the second
bevacizumab. The contact zone on the Fab depends on the
overall antibody configuration (symmetric vs. asymmetric).
To understand the stabilizing effect of dexamethasone phos-
phate, the ligand was docked all over the monomer anti-
body model. The highest docking scores were obtained for
the binding of the phosphate group to Lys445 at the aggre-
gation interface. Additional H-bonds between residues
adjacent to Lys445 and the phosphate further stabilize the
steroid in the binding pocket. Thus, dexamethasone phos-
phate masks the interaction interface between two mono-
mers and consequently hinders dimer formation through the
strong electrostatic interaction between the phosphate and
the side chain of Lys445. In vitro investigations support these
observations: Dexamethasone phosphate is able to partly
prevent or reverse aggregation of the antibody during the
stability studies.
It is shown that the 1:15 molar ratio bevacizumab:dexa-
methasone phosphate is optimal to stabilize the protein in
the commercial formulation at pH 6.2. Apparently, in a
formulation with a 1:1.5 ratio, the number of dexametha-
sone molecules is too low to interact with all antibodies
present, whereas the 1:150 ratio leads to the formation of
higher order aggregates. For betamethasone phosphate, the
1:15 combination was also observed to be the optimal molar
ratio (results on other molar ratios are not shown). A similar
importance for molar ratios was reported by Cleland et al.,
who studied the stabilizing effects of sugar on a lyophilized
monoclonal antibody: The molar ratio between stabilizing
agent and antibody was found to be a critical parameter in
the stabilizing process (30). It should be noted that the
1:15 molar ratio was observed to be optimal only for this
particular formulation. Since the dialysed formulation at pH
7 is different from the commercial one, it might not be the
optimal ratio at pH 7. This should be investigated in further
work.
Because an aggregation breaking effect of dexametha-
sone phosphate is observed during both thermal stress and
agitation, the assumption can be made that the form of
stress applied has no influence on the ability of the steroid
drug to hinder dimer formation. This observation may
suggest that the formation of bevacizumab aggregates is
similar for both thermal and mechanical stresses, at least
in the initial process of aggregation. In vitro measurements
show that the first aggregates observed are dimers (and low
percentages of trimers in the case of agitation) for both
stressing processes; higher order aggregates are only mea-
sured in later stages of the stress studies. Thus, in addition to
the 3D dimer model, these data imply that aggregation takes
place through a primary formation of dimers, which might
act as active nuclei for further aggregation. This said, it
should be noted that there is an important difference be-
tween aggregation formation due to thermal stress and
agitation. In the case of thermal stress, the corticosteroid is
able to cause reversion of formed aggregates back to mono-
mers (Fig. 5). However, the slope of the curve is comparable
to that of bevacizumab alone, i.e. the aggregation kinetics
are similar and the addition of the breaker does not slow
down the rate at which aggregates are formed. In contrast,
during agitation a clear stabilization of the aggregation
kinetics is observed: Fig. 4 shows that over time, the
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percentage of aggregates increases for the sample containing
bevacizumab only, whereas it stays almost the same when
dexamethasone phosphate is present.
To validate the aggregation model and to verify whether
the Fc region is indeed indispensable for aggregation, as
shown in the aggregation model, a negative control is per-
formed in vitro. Ranibizumab is a Fab fragment that has the
same sequence as a single Fab fragment of bevacizumab. If
the prediction of the aggregation model is correct, than the
assumption could be made that ranibizumab is less prone to
aggregation than the complete antibody bevacizumab, since
it lacks the Fc region that is involved in the aggregation
process. This is confirmed by comparing the aggrega-
tion profiles of bevacizumab and ranibizumab induced
by temperature stress: Ranibizumab is already more
stable than bevacizumab at t0 and stays more stable
over the whole study period, as was observed in earlier
work (12). Furthermore, the absence of the Fc region
implies that dexamethasone phosphate is unable to sta-
bilize ranibizumab: If dexamethasone phosphate inter-
acts with Lys 445 as proposed in the 3D model, than it
would be impossible to stabilize the aggregated Fab
fragment, which lacks this particular and surrounding
amino acids. Indeed, no significant difference is ob-
served between the aggregate percentages of ranibizu-
mab alone and in combination with dexamethasone
phosphate, thereby confirming the assumption.
A second validation of the aggregation model and the
assessment of the capacity of the procedure to distin-
guish between aggregation breakers and non-breakers in
a predictive way were performed by docking several
steroids onto the Fc contact region of the monomer.
Subsequently, the second monomer of the aggregation
model was displayed and the molecules were selected or
rejected based on their propensity of interfering with
dimer formation while binding to the first monomer.
It seems that phosphate is fundamental for the interac-
tion, since this negatively charged functional group can
form an electrostatic interaction with the (at physiolog-
ical pH) positively charged terminal amide of Lys445.
Of the tested steroids, betamethasone phosphate is pre-
dicted to be a bevacizumab-bevacizumab interaction
breaker, since its phosphate group is in a similar con-
figuration as in dexamethasone phosphate. Indeed, beta-
methasone phosphate shows a similar binding mode as
dexamethasone phosphate. The in vitro examination of
betamethasone phosphate shows that this molecule has a
similar aggregation breaking effect on bevacizumab as
was observed for dexamethasone phosphate, supporting
the predictability of the model.
Triamcinolone acetonide phosphate serves as a further
control for corroborating the model and the predictive-
ness of the compound selection procedure. In comparison
with both dexamethasone phosphate and betamethasone
phosphate, it is observed in vitro that triamcinolone ace-
tonide phosphate lacks the protective properties on this
particular antibody. By just looking at the presence of a
phosphate group, one might expect that triamcinolone
acetonide phosphate also has an aggregation breaking
effect on bevacizumab. However, when comparing the
docking results on the Fc contact region of triamcinolone
acetonide phosphate with the aggregation-breaking ste-
roids, it is shown that (i) the presence of the acetonide
moiety restricts the conformational flexibility so that
Lys445 is still able to interact with the phosphate, but
that (ii) the steroid part is oriented parallel to the Fc
surface and therefore (iii) not interfering with the adja-
cent antibody, since only the acetonide group is pointing
towards the other monomer, not being voluminous
enough to hinder dimer formation.
CONCLUSION
In this paper, the mechanism behind the aggregation break-
ing properties of dexamethasone phosphate on the mono-
clonal IgG1-based antibody bevacizumab was investigated.
In the proposed in silico model, interfering with dimer for-
mation is based on the ability of dexamethasone phosphate
(or betamethasone phosphate) to hinder the interaction
between the Fc part of the first, and the Fab arm of the
second bevacizumab monomer. In vitro, bevacizumab
dimers revert partly into monomers after addition of dexa-
methasone phosphate, independently of the form of stress
applied. This observation supports the idea that the mech-
anism behind the initial dimer formation of bevacizumab is
similar for these two forms of stress testing. As we have
shown, it is possible to predict whether a molecule has
aggregation breaking properties: In order to hinder the
dimer formation, a flexibly bending phosphate group is
required to accurately position the rest of the steroid.
Such flexibility is guaranteed in dexamethasone phos-
phate and betamethasone phosphate, but impossible in
triamcinolone acetonide phosphate due to the rigidity
conferred by its acetonide moiety.
This approach allows a simple way to stabilize therapeutic
antibodies without the need tomodify the Ig structure through
mutation of specific amino acids, which might lead to a loss in
efficacy. The therapeutic activity of the corticosteroids might
be an advantage in the development of a combination prod-
uct. However, further research will focus on the discovery of
safe and therapeutically inactive molecules with similar aggre-
gation breaking properties. Besides, supplementary studies on
unformulated bevacizumab need to be carried out to investi-
gate the contribution of polysorbate to the aggregation break-
ing effect of the anti-inflammatory drugs. The effects shown
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for the specific antibody bevacizumab might be applicable to
other IgG1 antibodies as well, which might be advantageous
for the future development of stable IgG1-derived antibodies.
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